NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis $20.33 -0.41 (-1.98%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$20.12▼$21.0050-Day Range$19.26▼$24.7952-Week Range$18.69▼$56.04Volume260,259 shsAverage Volume596,338 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$62.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Prothena alerts: Email Address Prothena MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside209.2% Upside$62.86 Price TargetShort InterestBearish10.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.58) to ($4.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.89 out of 5 starsMedical Sector794th out of 910 stocksPharmaceutical Preparations Industry370th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProthena has only been the subject of 3 research reports in the past 90 days.Read more about Prothena's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.01% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 1.1 News and Social Media Coverage Search Interest3 people have searched for PRTA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prothena's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($2.58) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prothena's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Prothena Stock (NASDAQ:PRTA)Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Read More PRTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Stock News HeadlinesAugust 29, 2024 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 23, 2024 | ca.finance.yahoo.comPRTA Sep 2024 35.000 putSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 18, 2024 | msn.comProthena Corporation plc (PTRA): Positioning Among Top Debt-Free StocksAugust 14, 2024 | ca.finance.yahoo.comBMY Sep 2024 43.000 putAugust 14, 2024 | ca.finance.yahoo.comBMY Aug 2024 43.000 putAugust 13, 2024 | ca.finance.yahoo.comBMY Aug 2024 41.000 putAugust 13, 2024 | ca.finance.yahoo.comBMY Sep 2024 47.000 putSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)August 9, 2024 | stockhouse.comProthena Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 9, 2024 | markets.businessinsider.comTime To Tune In To Prothena?August 9, 2024 | investorplace.comPRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024August 7, 2024 | markets.businessinsider.comProthena earnings: here's what Wall Street expectsAugust 4, 2024 | finance.yahoo.comWhile shareholders of Prothena (NASDAQ:PRTA) are in the black over 5 years, those who bought a week ago aren't so fortunateAugust 1, 2024 | businesswire.comProthena to Report Second Quarter 2024 Financial Results on August 8July 22, 2024 | finance.yahoo.comPRTA Aug 2024 17.500 put (PRTA240816P00017500)June 7, 2024 | seekingalpha.comProthena: Potential For Future Price Drop On Failure Risk Of Late-Stage TrialsSee More Headlines Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees130Year FoundedN/APrice Target and Rating Average Stock Price Target$62.86 High Stock Price Target$87.00 Low Stock Price Target$24.00 Potential Upside/Downside+209.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,030,000.00 Net Margins-23.44% Pretax Margin-28.26% Return on Equity-9.00% Return on Assets-7.51% Debt Debt-to-Equity RatioN/A Current Ratio12.54 Quick Ratio12.54 Sales & Book Value Annual Sales$217.25 million Price / Sales5.03 Cash FlowN/A Price / Cash FlowN/A Book Value$10.46 per share Price / Book1.94Miscellaneous Outstanding Shares53,772,000Free Float38,608,000Market Cap$1.09 billion OptionableOptionable Beta0.18 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Gene G. Kinney Ph.D. (Age 55)President, CEO & Director Comp: $1MMr. Tran B. Nguyen M.B.A. (Age 50)CFO & Chief Strategy Officer Comp: $830.14kMr. Brandon S. Smith (Age 49)Chief Operating Officer Comp: $757.79kMs. Carol D. Karp (Age 71)Chief Regulatory Officer Comp: $701.48kDr. Hideki Garren M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $808.71kMs. Karin L. Walker CPA (Age 61)Chief Accounting Officer & Controller Dr. Wagner M. Zago (Age 51)Chief Scientific Officer Comp: $478.79kMr. Mark C. Johnson C.F.A.Vice President of Investor RelationsMr. Michael J. Malecek (Age 58)Chief Legal Officer Comp: $588.25kMr. David A. Ford (Age 54)Chief People Officer More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXUroGen PharmaNASDAQ:URGNAkebia TherapeuticsNASDAQ:AKBAPuma BiotechnologyNASDAQ:PBYIMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsSystematic Financial Management LPBought 39,771 shares on 8/16/2024Ownership: 0.360%Algert Global LLCBought 28,841 shares on 8/16/2024Ownership: 0.144%Armistice Capital LLCBought 464,000 shares on 8/15/2024Ownership: 2.901%Profund Advisors LLCSold 28,805 shares on 8/14/2024Ownership: 0.034%DCF Advisers LLCBought 500 shares on 8/13/2024Ownership: 0.200%View All Insider TransactionsView All Institutional Transactions PRTA Stock Analysis - Frequently Asked Questions How have PRTA shares performed this year? Prothena's stock was trading at $36.34 at the start of the year. Since then, PRTA shares have decreased by 44.1% and is now trading at $20.33. View the best growth stocks for 2024 here. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) released its earnings results on Thursday, August, 8th. The biotechnology company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($1.01) by $2.23. Prothena's revenue for the quarter was up 3184.7% on a year-over-year basis. Who are Prothena's major shareholders? Prothena's top institutional shareholders include Armistice Capital LLC (2.90%), Dimensional Fund Advisors LP (1.60%), Renaissance Technologies LLC (0.61%) and Systematic Financial Management LP (0.36%). Insiders that own company stock include Ecor1 Capital, Llc, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp, Wagner M Zago and Brandon S Smith. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Cara Therapeutics (CARA), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT) and BioLineRx (BLRX). This page (NASDAQ:PRTA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
